Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Tangen

Showing results (11-20 of 217) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|November 9, 2024
Adjuvant everolimus after renal cell carcinoma nephrectomy - Authors' replyChristopher W Ryan, Catherine M Tangen, Primo N Lara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Is there a standard of care for pathologic stage T3 prostate cancer?Ian M Thompson, Catherine M Tangen, Eric A Klein
The New England Journal of Medicine|November 15, 2013
Survival in the prostate cancer prevention trialCatherine M Tangen, Phyllis J Goodman, Ian M Thompson
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ReplyPhyllis J Goodman, Catherine M Tangen, Ian M Thompson
Asian Journal of Andrology|June 11, 2014
Re: Long-term survival of participants in the Prostate Cancer Prevention TrialIan M Thompson, Catherine M Tangen, Phyllis J Goodman
The Journal of Urology|December 13, 2002
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioningTracy R Glass, Catherine M Tangen, E David Crawford, et al.
Electronic Journal of Statistics|August 24, 2019
Robustifying Trial-Derived Optimal Treatment Rules for A Target PopulationYing-Qi Zhao, Donglin Zeng, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Biased hormonal therapy duration analysis makes results uninterpretableCatherine M Tangen, Bryan H Goldman, Gregory P Swanson, et al.
The Journal of Urology|January 10, 2004
Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trialsCatherine M Tangen, Phyllis J Goodman, John J Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Phase III prostate cancer prevention trials: are the costs justified?Ian M Thompson, Catherine M Tangen, Eric A Klein, et al.
Pageof 22

Showing results (11-20 of 217) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|November 9, 2024
Adjuvant everolimus after renal cell carcinoma nephrectomy - Authors' replyChristopher W Ryan, Catherine M Tangen, Primo N Lara
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Is there a standard of care for pathologic stage T3 prostate cancer?Ian M Thompson, Catherine M Tangen, Eric A Klein
The New England Journal of Medicine|November 15, 2013
Survival in the prostate cancer prevention trialCatherine M Tangen, Phyllis J Goodman, Ian M Thompson
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ReplyPhyllis J Goodman, Catherine M Tangen, Ian M Thompson
Asian Journal of Andrology|June 11, 2014
Re: Long-term survival of participants in the Prostate Cancer Prevention TrialIan M Thompson, Catherine M Tangen, Phyllis J Goodman
The Journal of Urology|December 13, 2002
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioningTracy R Glass, Catherine M Tangen, E David Crawford, et al.
Electronic Journal of Statistics|August 24, 2019
Robustifying Trial-Derived Optimal Treatment Rules for A Target PopulationYing-Qi Zhao, Donglin Zeng, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Biased hormonal therapy duration analysis makes results uninterpretableCatherine M Tangen, Bryan H Goldman, Gregory P Swanson, et al.
The Journal of Urology|January 10, 2004
Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trialsCatherine M Tangen, Phyllis J Goodman, John J Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Phase III prostate cancer prevention trials: are the costs justified?Ian M Thompson, Catherine M Tangen, Eric A Klein, et al.
Pageof 22